Side-by-side · Research reference

CJC-1295 (no DAC)vsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1Reviewed15/51 cited

BPhase 3Draft10/40 cited

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer doseTeichman 2006

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

CJC-1295 (no DAC)

Tesofensine

Primary target

Pituitary GHRH receptorTeichman 2006

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

—

Origin

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

Not reported in short-term studies

—

02Dosage Protocols

Parameter

CJC-1295 (no DAC)

Tesofensine

Standard dose

100 mcg per injectionTeichman 2006

Often paired with ipamorelin in same syringe.

0.25–0.5 mg / dayAstrup 2008

Frequency

1–2× daily (pre-sleep ± morning)

Once daily, morning

Lower / starter dose

50 mcg per dose

0.125 mg / day

Evidence basis

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

Phase 2b + ongoing Phase 3Astrup 2008

Duration

8–12 weeks on / 4 off (anecdotal)

24 weeks per studied cycle

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep + fasted preferred

Morning to avoid sleep disruption

Half-life

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

~9 days (very long)

Form

—

Oral capsule

04Side Effects & Safety

Parameter

CJC-1295 (no DAC)

Tesofensine

Injection site reaction

Erythema, mild pruritus

—

Flushing / headache

Common transient effect

—

Cortisol elevation

Minimal at standard doses

—

Prolactin elevation

Minimal

—

Glucose intolerance

Possible at high cumulative doses

—

IGF-1 elevation

Dose-dependent; monitor with chronic use

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis)

—

Pregnancy / OB

Avoid

Contraindicated

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Nausea

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Absolute Contraindications

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

CJC-1295 (no DAC)

Tesofensine

1. Reconstitution

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

Oral capsule (investigational; not commercial).

2. Injection site

Subcutaneous, abdomen or thigh. Rotate sites.

Swallow whole with water, morning only.

3. Timing

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

Morning to mitigate insomnia. Do not dose evening.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Room temp ≤25 °C, dry place.

5. Needle

29–31G, 4–8 mm insulin syringe.

Monitor BP + HR + mood. Avoid stimulants + MAOIs.

06Stack Synergy

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Teichman 2006 Raun 1998

Tesofensine

— no documented stacks